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Abstract. To investigate the potential added value of intranasal drug administration, preclinical studies to
date have typically used the area under the curve (AUC) in brain tissue or cerebrospinal fluid (CSF)
compared to plasma following intranasal and intravenous administration to calculate measures of extent
like drug targeting efficiencies (%DTE) and nose-to-brain transport percentages (%DTP). However,
CSF does not necessarily provide direct information on the target site concentrations, while total brain
concentrations are not specific to that end either as non-specific binding is not explicitly considered.
Moreover, to predict nose-to-brain transport in humans, the use of descriptive analysis of preclinical data
does not suffice. Therefore, nose-to-brain research should be performed translationally and focus on
preclinical studies to obtain specific information on absorption from the nose, and distinguish between
the different transport routes to the brain (absorption directly from the nose to the brain, absorption
from the nose into the systemic circulation, and distribution between the systemic circulation and the
brain), in terms of extent as well as rate. This can be accomplished by the use of unbound concentrations
obtained from plasma and brain, with subsequent advanced mathematical modeling. To that end, brain
extracellular fluid (ECF) is a preferred sampling site as it represents most closely the site of action for
many targets. Furthermore, differences in nose characteristics between preclinical species and humans
should be considered. Finally, pharmacodynamic measurements that can be obtained in both animals and
humans should be included to further improve the prediction of the pharmacokinetic–pharmacodynamic
relationship of intranasally administered CNS drugs in humans.
KEY WORDS: advanced mathematical modeling; blood–brain barrier; central nervous system;
intranasal drug administration; nose-to-brain transport; translation.
INTRODUCTION
Over the past few decades, an increasing effort has been
put into research focusing on the central nervous system
(CNS) and its disease conditions (1). This allowed the
identification of new drug targets due to an improved
understanding of CNS disease etiologies and pathologies.
Consequently, scientists were provided with opportunities to
develop novel drugs for CNS diseases. Despite this progress in
neurosciences, the development of CNS-active drugs remains
highly challenging as shown by relatively high attrition rates of
drugs during clinical trials (2). Numerous candidate drugs for
CNS diseases were efficacious during in vitro and preclinical
in vivo studies. However, many of these drugs did not show
efficacy when administered in humans. One important reason
for this may be the lack of having the drug at the right time, at
the right concentration, and at the right place (3).
The presence of the blood–brain barriers has typically
been seen as an important reason for these problems and the
intranasal (IN) route of administration has been implicated to
circumvent these barriers, as direct absorption from the nose
to the brain might exist (4). As human brain sampling is
highly restricted, animal data should mainly provide insight
into possible brain distribution enhancement via the IN route.
This review aims to provide insight in advanced exper-
imental and mathematical modeling approaches using
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preclinical data, and proposed steps to be taken for transla-
tion between conditions and ultimately to species translat-
ability for nose-to-brain transport in humans. To that end, the
impact of the blood–brain barriers on drug distribution into
the CNS is shortly discussed, followed by a summary on the
knowledge of the nasal anatomy, histology, and physiology
and their species differences; direct nose-to-brain drug
transport mechanisms; evidence for direct nose-to-brain drug
and drug delivery systems transport in animals; and evidence
for direct nose-to-brain drug transport in humans. Then
examples follow on the design of a translational preclinical
pharmacokinetic–pharmacodynamic (PK-PD) study on
remoxipride following intravenous (IV) and IN administra-
tion, and the successful PK-PD translation of IV administered
remoxipride from rats to humans. All together, this informa-
tion finally feeds into considerations and suggestions for
future studies on translation of preclinical nose-to-brain PK
and PK-PD data to the human situation.
INTRANASAL ADMINISTRATION TO CIRCUMVENT
THE IMPACT OF THE BLOOD–BRAIN BARRIERS
ON DRUG DISTRIBUTION INTO THE CNS
Various drugs do not adequately reach CNS target sites
due to the blood–brain barrier (BBB), the blood cerebrospi-
nal fluid barrier (BCSFB), and the arachnoid barrier (5).
These barriers not only protect the CNS from invading
pathogens and various toxic substances but also provide an
interface for blood–CNS exchange (6). The BBB is located in
the endothelium of brain capillaries. The combined surface
area of these brain capillaries makes it by far the largest
blood–CNS interface. Therefore, most CNS-active drugs tend
to enter the brain mainly by passing through the BBB.
Drug transport via the BBB can be limited in two ways.
For hydrophilic drugs that cannot traverse cell membranes
easily, paracellular transport across the BBB is highly
restricted and only possible for the smaller sized ones, as
tight junctions create a firm connection between adjacent
endothelial cells. For the more lipophilic drugs that can pass
cell membranes readily, transcellular passage of the BBB may
be counteracted by the action of efflux transporter proteins,
such as P-glycoprotein (Pgp) and multidrug resistance-related
proteins (MRPs) that are present on the cell membranes of
the brain capillary endothelial cells. Not all transporter
proteins counteract drug transport across the BBB; some
influx transporters actually aid the access of drugs to the
brain. Thus, the BBB can play an important role in drug
distribution into the CNS and therewith also in CNS target
site distribution of drugs.
Knowledge of the BBB and its mostly limiting effect on
CNS drug distribution has guided researchers to investigate
and to develop novel drug delivery techniques which are
capable of circumventing this barrier. Methods to bypass the
BBB include opening of the tight junctions between endo-
thelial cells to enhance the transport of hydrophilic drugs
though paracellular diffusion (6). However, opening tight
junctions also makes the brain more vulnerable to the entry
of unwanted organisms and substances. The BBB can also be
circumvented by using intracerebral implants and intraven-
tricular infusions (7). Both of these drug delivery methods are
very invasive and are usually only considered when no other
methods are possible. So, there is a need for safer, easier, and
less invasive brain drug delivery techniques which bypass the
BBB.
Researchers answered to this need by exploring IN drug
administration as a method to enhance the delivery of drugs
into the brain while bypassing the BBB (8). This Bdirect nose-
to-brain^ transport is anticipated to offer several advantages
in comparison to other drug delivery techniques. Firstly, IN
delivery avoids the first-pass effect which improves the
bioavailability of a drug. Secondly, there is a potential for
direct nose-to-brain delivery as drugs could bypass the BBB.
Thirdly, absorption of drugs by the nasal mucosa could
produce a fast onset of therapeutic effects. Lastly, IN delivery
is minimally invasive which may promote medication adher-
ence in patients. Thus, direct nose-to-brain delivery could be
a promising drug administration technique for patients who
suffer from CNS diseases.
Many animal studies have shown that drugs administered
via the IN route can enter the brain, although a relatively
modest percentage of those studies present quantitative PK data
to confirm the extent of direct nose-to-brain transport (9,10).
Moreover, these studies were performed with animals, mostly
rats, which have significantly different nasal features when
compared to humans. This restricts the predictive value of
preclinical animal models, though it is reasonable to assume that
high direct nose-to-brain transport in humans is unlikely to
occur if very low transport is observed in animals. It is
anticipated that proper understanding of and progress in
application of predictive approaches for PK and PK-PD data
to be translated from animals and humans will lead to an
improved predictive value. Ultimately, this will aid the transla-
tion of nose-to-brain transport from animals to humans.
Therefore, first insight into nasal characteristics is essential.
NASAL ANATOMY, HISTOLOGY, AND PHYSIOLOGY
AND SPECIES DIFFERENCES
Nasal Anatomy
The human nasal cavity is a structure which connects the
nostrils to the nasopharynx and is split in a longitudinal
manner by the nasal septum (see Fig. 1) (11,12). In humans,
the nasal cavity has an approximate length of 12–14 cm and a
height of 5 cm. Furthermore, the nasal cavity has a surface
area of 160 cm2. This surprisingly large surface area is partly
created by the nasal turbinates. Nasal turbinates are
horizontal bony structures shaped like scallop seashells.
Each nasal cavity contains three turbinates (inferior, middle,
and superior) which are present on the lateral wall.
Additionally, the nasal cavity contains two functional
regions which are concerned with (a) the conditioning and
filtration of inhaled air before it enters the lungs (respiratory
region) and (b) the sense of smell (olfactory region).
Another unique feature of the nasal cavity is its rich
vasculature which aids the conditioning of inhaled air. Both
the nasal septum and the lateral wall of the nasal cavity
receive blood from the anterior ethmoidal, posterior ethmoi-
dal, and sphenopalatine arteries (11). The nasal septum also
obtains blood from branches of the superior labial artery and
of the greater palatine artery. Additionally, the nasal vestibule
gains blood from the lateral nasal artery. Finally, blood is
494 Ruigrok and Lange
drained into the ophthalmic vein, the cavernous sinus, and the
pterygoid plexus.
Nerves in the nasal cavity are responsible for the transfer of
chemosensory (chemicals and odors), nociceptive (pain),
thermoceptive (temperature), and mechanoceptive (touch)
information to the CNS. Firstly, olfactory sensory neurons
(OSNs) are located in the olfactory region and their dendrites
converge into the olfactory nerve which travels through the
cribriform plate and ends up in the olfactory bulb. OSNs are
bipolar neurons as they have only one axon and one dendrite (9).
Their axons are located in the nasal epithelia where they extend
surprisingly deep into the mucous layer. This feature benefits
olfaction as it makes OSN receptors more accessible to odorants.
Furthermore, the respiratory and olfactory region are
innervated by branches of the trigeminal nerve (i.e., the
ophthalmic nerve, the maxillary nerve, and the mandibular
nerve) which terminates in the trigeminal nuclei of the brainstem
(9,13). However, the mandibular nerve does not innervate the
nasal epithelium. Hence, innervation of the olfactory region and
the respiratory region is only provided by the ophthalmic nerve
and the maxillary nerve, respectively. Finally, free nerve endings
of the ophthalmic nerve and the maxillary nerve extend into the
surface epithelium, but they do not reach further than the level of
tight junctions (14). Here, they transmit chemosensory informa-
tion from the nasal cavity to the brain.
Nasal Histology
Four types of epithelium can be found in the nasal cavity:
squamous, transitional, respiratory, and olfactory (15). These
types of epithelium line the surface of distinct regions in the
nasal cavity. Firstly, squamous epithelium covers the nasal
vestibule and it extends to the anterior side of the inferior
nasal turbinate. Secondly, a narrow lining of transitional
epithelium connects squamous epithelium with respiratory
epithelium and respiratory epithelium with olfactory epithe-
lium. Thirdly, respiratory epithelium lines the main chamber
of the nasal cavity and the nasopharynx. Lastly, olfactory
epithelium is present on the cranial side of the nasal cavity.
Squamous epithelium is composed of lightly keratinized
stratified squamous cells and basal cells. Like the skin,
squamous epithelium is thought to protect underlying tissue
from toxic substances. Transitional epithelium consists of
non-ciliated microvilli-covered cells and basal cells. Luminal
non-ciliated transitional epithelium contains an abundance of
smooth endoplasmic reticulum which might play a role in the
metabolism of inhaled xenobiotics (15). Respiratory epitheli-
um is mainly comprised of ciliated pseudostratified cells,
although it also consists of mucous, non-ciliated, columnar,
cuboidal, brush, and basal cells. Several xenobiotic metabo-
lizing enzymes (e.g., carboxylesterase, aldehyde dehydroge-
nase, and cytochrome P-450) have been identified in
respiratory epithelium (15). Lastly, olfactory epithelium is
composed of three cell types: olfactory sensory neurons,
sustentacular cells, and basal cells. Upon neuronal cell loss,
olfactory sensory neurons regenerate (neurogenesis) to
preserve the ability of olfaction.
The respiratory and olfactory epithelia are the main
absorption sites for direct nose-to-brain drug delivery.
However, olfactory epithelium is the most relevant for direct
nose-to-brain delivery as it provides a direct link between the
nasal cavity and the CNS which bypasses the BBB (13).
Nasal Physiology
The nasal cavity has several important functions. Aside
from olfaction (i.e., the sense of smell), the nasal cavity is
involved in conditioning inhaled air (12). Inhaled air is heated,
humidified, and filtered before it enters the lungs, which limits
bronchial heat loss and tissue damage. Arteriovenous anasto-
moses in the nasal cavity aid the exchange of heat from arterial
blood to inhaled air. Furthermore, the small width of the nasal
cavity facilitates close contact between the mucous layer and
inhaled air. Consequently, the nasal cavity conditions room air
from 23°C with a relative humidity of 40 to 32°C and a relative
humidity of 98%.
In addition, inhaled air is filtered before it enters the lungs
because clearance of harmful agents becomes significantly more
difficult when they are deposited into bronchi and alveoli.
Filtration of air occurs as harmful agents are deposited into
mucus which is present on the surface epithelium of the nasal
cavity. Mucus is produced by Goblet cells and it contains
antimicrobial enzymes, immunoglobulins, and lactoferrins
(16,17). Furthermore, mucus is constantly pushed towards the
nasopharynx by motile cilia which are present on ciliated cells.
Finally, the fate of mucus is either expectoration or swallowing.
This whole process is called mucociliary clearance, and it results
in a nasal clearance half-time of approximately 15 to 20 minutes
for most non-mucoadhesive substances (18). Interestingly,
olfactory epithelium lacks cilia mobility which results in reduced
mucociliary clearance. On the other hand, respiratory epitheli-
um contains ciliated cells, resulting in more prominent
mucociliary clearance (13).
Species Differences
For the predictive value of preclinical animal models for
the human situation, it is important to realize that major
differences exist in nasal features between conditions, such as
species differences, especially between animals and humans
Fig. 1. General anatomical features of the lateral wall of the human
nasal cavity. NV Nasal vestibule, IT inferior turbinate, MT middle
turbinate, ST superior turbinate
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(9,19,20). Rats are used most often as a preclinical animal
model in direct-nose-to-brain drug delivery studies, although
mice and rabbits are used as well. In Table I, it can be seen
that the relative absorption area is much larger (8-fold) in rats
than in humans. Humans have an average bodyweight, a
nasal cavity volume (NCV), and a nasal cavity surface area
(NCSA) of 70 kg, 25 and 160 cm2, respectively. This yields a
relative surface area (NCSA/NCV) of 6.4 cm−1 in humans.
Rats have an average bodyweight, NCV, and NCSA of
0.25 kg, 0.26 and 13.4 cm2, respectively. Therefore, it can be
generally said that direct nose-to-brain delivery obtained
from rats will overestimate direct nose-to-brain transport in
humans if differences in the relative surface area are not
adequately accounted for.
NOSE-TO-BRAIN DRUG TRANSPORT MECHANISMS
IN administered drugs can reach the CNS via three
transport mechanisms (13). Firstly, drugs can enter the CNS
via the olfactory bulb by transport along the olfactory nerve.
Secondly, drugs can enter the CNS by transport via the
trigeminal nerve. These two drug transport mechanisms
circumvent the BBB, resulting in direct nose-to-brain
transport. Lastly, drugs can enter the systemic circulation
by absorption through arteriovenous anastomoses.
Thereafter, drugs in the systemic circulation can enter
the brain by crossing the BBB. Collectively, these
mechanisms can be used to deliver drugs from the nasal
cavity into the CNS.
Olfactory Nerve Direct Nose-to-Brain Transport
The olfactory nerve is likely to be the most important in
direct nose-to-brain drug delivery, although more research is
necessary in this field (18,21,22). OSNs in the olfactory region
regenerate every 3–4 weeks which may result in a decreased
barrier function due to a combination of factors. For instance,
tight junction proteins, efflux transporters, and proteolytic
enzymes might not be fully present or functional during the
regeneration process, resulting in a Bleaky barrier^ (13,23).
This decreased barrier function can be exploited to achieve
direct nose-to-brain drug delivery. Intranasally administered
drugs can reach the CNS via the olfactory pathway in two
ways. Firstly, drugs can diffuse into the extracellular spaces of
the olfactory nerve bundles. Subsequent transport to the
olfactory bulb is likely to depend on a combination of bulk
movement and propagation of action potentials along the
olfactory nerves. Secondly, drugs can be transported via
intracellular mechanisms such as passive diffusion, adsorptive
endocytosis, and receptor-mediated endocytosis. However,
extracellular transport along the olfactory nerves is faster
(minutes to half an hour) than intracellular transport (hours
to days) (13). Upon reaching the olfactory bulb and
cerebrospinal fluid (CSF), drugs can access other regions of
the CNS by bulk flow mechanisms and by mixing with brain
extracellular fluid (ECF).
Trigeminal Nerve Direct Nose-to-Brain Transport
Direct nose-to-brain drug delivery can also occur to a
lesser extent via transport along the trigeminal nerve.
Branches of the trigeminal nerve innervate both the respira-
tory and olfactory regions in the nasal cavity, as mentioned
earlier. After passing through the respiratory and olfactory
epithelium, drugs can move along the trigeminal nerve via
intracellular or extracellular transport mechanisms where
they can enter the brain through either the cribriform
plate or the pons. Interestingly, the distance between the
nasal epithelium and the brainstem (trigeminal pathway)
in rats is estimated to be ∼20–30 mm, while the distance
from the olfactory epithelium to the olfactory bulb
(olfactory pathway) is estimated to be ∼4–5 mm. Once
present in the brain, drugs can diffuse through the CSF
and brain ECF in order to reach other CNS regions.
Unfortunately, the degree of transport attributable to this
route is not fully understood.
Nose-to-Brain Transport via Initial Absorption
in the Systemic Circulation Followed by BBB Transport
Lastly, various small molecules and biomacromolecules
administered via the IN route have been shown to enter the
CNS by initial absorption into the systemic circulation and
subsequent transport through the BBB (24). Initial absorp-
tion into the blood is restricted by three barriers: the mucous
layer, the epithelial membrane, and the junctional barrier
(16). Initial diffusion of drugs into mucus has been shown to
be highly dependent on lipophilicity (25). Next, drugs have to
cross the nasal epithelium by either transcellular or
paracellular transport. Lipophilic drugs cross this barrier via
transcellular transport by partitioning into the lipid bilayers of
cells. Additionally, transcellular transport can also occur by
receptor-mediated or vesicular transport (26). Paracellular
transport of hydrophilic molecules is highly limited by its
Table I. Anatomical and Histological Differences Between The Nasal Cavity of Mice, Rats, Rabbits, and Humans (9,11,12)
Parameter Mice Rats Rabbits Humans
Bodyweight (kg) 0.03 0.25 3 70
Nasal cavity volume (cm3) 0.03 0.26 6 25
Nasal cavity surface area (cm2) 2.89 13.4 61 160
Relative surface area (NCSA/NCV)(cm-1) 96.3 51.5 10.2 6.4
Olfactory epithelium (% of NCSA) 47 50 10 8
Olfactory epithelium (cm3) 1.37 6.75 6 12.5
The relative surface area of the nasal cavity in mice, rats, and rabbits is higher than in humans. Furthermore, mice and rats have a substantially
higher relative amount of olfactory epithelium (% of NCSA) than humans (factor 15 and 8, respectively) (9,11,12)
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weight as they have to passively diffuse through tight
junctions. Generally, paracellular transport only occurs when
drugs have a molecular weight <1000 Da (26). Afterwards,
drugs which passed these barriers will enter the venous blood
flow. In order to reach the CNS, drugs also have to pass the
BBB, which has been addressed shortly in a previous section.
In conclusion, drugs can also reach the CNS via
initial absorption into the systemic circulation, followed by
blood-brain transport.
Physicochemical Properties of Drugs
Absorption of drugs via the nasal cavity into the systemic
circulation is highly dependent on physicochemical properties
of drugs (24). However, not much is known about statistically
significant correlations between the efficiency of direct nose-
to-brain transport and the physicochemical properties of IN
administered drugs (10,27). Although many different drug
types (small molecules, biomacromolecules, and specialized
drug delivery systems) have been shown to enter the brain via
direct nose-to-brain transport, both Kozlovskaya et al. (2014)
and Lee et al. (2010) were unable to identify correlations
between the extent of direct nose-to-brain transport and the
molecular weight (MW), partition coefficient (LogP, which
describes the partition of unionized compounds in two
immiscible phases), and distribution coefficient (LogD, which
describes the total partition of both ionized and unionized
compounds in two immiscible phases, and as such is
dependent on pH) (10,27). However, these results are in
contrast with the findings obtained by Sakane et al. (1991)
and Chou and Donnovan (1998) who observed a statistically
significant correlation between lipophilicity of compounds
and drug concentrations in the CSF after IN administration
(28,29). On the basis of these studies performed so far, no
conclusions can be drawn about the influence of physico-
chemical properties of drugs and nose-to-brain transport, and
further investigations are needed to allow a more rational
approach to drug design.
Active Transport and Metabolizing Mechanisms
Finally, it is important to realize that in direct nose-to-
brain transport, drug transporters and metabolizing capacity
of nasal mucosa should be considered as well. Graff and
Pollack (2003) have shown that P-glycoprotein may diminish
brain accumulation of intranasally administered P-
glycoprotein substrates (30). In addition, the metabolic
capacity of the nasal mucosa can be modified by metabolizing
enzymes (31). Wong and Zuo (2010) highlighted the impor-
tance and implications of how nasal metabolism might
influence the transport of drugs via direct nose-to-brain
transport. For instance, research has shown metabolizing
enzymes (e.g., cytochrome P-450) are present in the nasal
mucosa of rats and humans which might limit direct nose-to-
brain transport of xenobiotics (32). Furthermore, qualitative
and quantitative differences in nasal metabolic enzymes exist
between animals and humans (33). Thus, taking into account
only the differences in the relative absorption area of the nose
in animals and humans alone might not be enough for
successful translation of direct nose-to-brain transport from
animals to humans.
EVIDENCE FOR NOSE-TO-BRAIN DRUG AND DRUG
DELIVERY SYSTEM TRANSPORT IN ANIMALS
Numerous animal studies have been performed inwhich IN
delivery of drugs into the brain was investigated for various
substances (e.g., small molecules, biologics, and specialized drug
delivery systems). The main goal of this section is to highlight
the large variety in the types of substances which were shown to
enter the CNS via direct nose-to-brain transport (see Table II)
without aiming to provide a complete list of all relevant
substances, but merely to present a selection of studies where
quantitative PK data was available that confirmed direct nose-
to-brain drug transport. Kozlovskaya et al. (2014) have present-
ed a more extensive list on the extent of direct nose-to-brain
drug transport for a large amount of substances which were
shown to enter the CNS via direct nose-to-brain transport (10).
The extent was based on AUC values in brain and plasma
following IVand IN drug administration, and expressed as drug
targeting efficiency percentage (%DTE) and the nose-to-brain
direct transport percentage (%DTP). Here, drug targeting
efficiency percentage is calculated as
%DTE ¼ AUCbrain=AUCbloodð Þin½ = AUCbrain=AUCbloodð Þiv½ 
 100%
where AUCbrain is the area under the concentration-time
curve of the compound in the brain (whole brain, or specific
parts such as CSF), AUCblood is the area under the curve of
the compound in the systemic circulation (blood, or plasma,
serum) and in and iv indicate intranasal or intravenous
administration, respectively. The nose-to-brain direct trans-
port percentage is calculated as
%DTP ¼ Bin−Bxð Þ=Bin  100%
With:
Bx ¼ Biv=Piv½ :Pin
where Bx is the brain AUC fraction contributed by the
systemic circulation through the BBB following IN adminis-
tration, Bin is the brain AUC over time following IN
administration, Piv is the blood AUC over time following IV
administration, and Pin is the blood AUC over time following
IN administration.
Small Molecule Drugs
Several IN administered small molecule drugs have been
shown to be delivered into the CNS via direct nose-to-brain
transport. For example, Chou and Donnovan (1998) detected
procaine, tetracaine, bupivacaine, and lidocaine in the CSF of
the cisterna magna in rats following IN administration with a
relative bioavailability (AUCintranasal/AUCintra-arterial) of 43%
for procaine and 100% for tetracaine, buvicaine, and
lidocaine (29). Procaine, tetracaine, bupivacaine, and
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lidocaine have distribution coefficients (LogDoctanol/water) of
−0.092, 2.18, 2.22, and 1.55. Therefore, the authors of this
study argued that the low bioavailability of procaine might be
caused by a lower distribution coefficient.
Furthermore, Stevens et al. (2011) showed that IN
administered remoxipride had a total bioavailability of 89%.
Total bioavailability was defined as the sum of the bioavail-
ability to the central compartment (22%) and the bioavail-
ability of direct nose-to-brain drug transport (67%) (34). This
indicates that for remoxipride in the rat, the bioavailability to
the brain by direct nose-to-brain transport is substantial. As
lipophilic compounds such as remoxipride (LogP=2.1) are
generally more readily absorbed into the mucus layer than
hydrophilic compounds (25,58), preferential absorption of
remoxipride into the systemic circulation was expected to
occur. However, this was not the case for remoxipride. This
indicates that other processes seem to be involved that favor
direct nose-to-brain transport, especially as the IN adminis-
tration of the moderately lipophilic drug acetaminophen did
not lead to brain distribution enhancement (35). Therefore, it
seems that lipophilicity does not play an obvious role in direct
nose-to-brain transport. Lastly, the opioid analgesic drug mor-
phine was detected in brain homogenates of rats after IN
administration (36). In comparison to IV drug administration a
significantly faster distribution of morphine in the brain hemi-
spheres was observed after initial transport through the olfactory
bulb (36). Collectively, these results show several CNS-active
small molecule drugs are transported into the CNS of rats via
direct nose-to-brain transport.
Biologics
Aside from small molecule drugs, peptides have also
been shown to enter the CNS via direct nose-to-brain drug
transport. Peptides are large molecules consisting of amino
acid monomers which are covalently linked to each other with
peptide bonds. Galanin-like peptide (MW=6.5 kDa), [Ser(
(2))] exendin (1–9) (MW=980 Da), and pituitary adenylate
cyclase-activating polypeptide (MW=4.5 kDa) were observed
in the CNS of mice after IN administration (18,21,22).
Additionally, neuroprotective peptide NAP (MW 825=Da),
calcitonin gene-related peptide (MW=3.8 kDa), and
hypocretin-1 (MW=3.6 kDa) were able to reach the CNS of
rats by direct nose-to-brain transport mechanisms (37–40).
Proteins have also been shown to enter the CNS after IN
drug administration in rats via direct nose-to-brain transport.
Therefore, IN drug administration provides an interesting
method to circumvent the BBB for proteins. Several studies
have shown that the following proteins were present in the
CNS of rats after IN administration: insulin growth factor 1
(MW=7.65 kDa), erythropoietin (30–34 kDa), interferon β1b
Table II. Overview of Direct Nose-to-Brain Transport Animal Studies Cited in this Current Review
Type Subtype Author (year) Substance(s) Animal used




Stevens et al. (2011) (34) Remoxipride Rats
Stevens et al. (2009) (35) Acetaminophen Rats
Westin et al. (2006) (36) Morphine Rats
Biologics Peptides Banks et al. (2004) (18) Galanin-like peptide Mice
Nonaka et al. (2008) (22) [Ser( (2))] exendin (1–9) Mice
Rat et al. (2011) (37) Pituitary adenylate cyclase-activating polypeptide Mice
Gozes et al. (2000) (38) Neuroprotective peptide NAP Rats
Sun et al. (2009) (39) Calcitonin gene-related peptide Rats
Dhuria et al. (2009) (40) Hypocretin-1 Rats
Proteins Thorne et al. (2004) (41) Insulin growth factor 1 Rats
Yu et al. (2005) (42) Erythropoietin Rats
Ross et al. (2004) (43) Interferon β1b Rats
Migliore et al. (2010) (44) Ovalbumin Rats
Fliedner et al. (2006) (45) Leptin Rats
Chen et al. (1998) (46) Human nerve growth factor Rats
Yang et al. (2009) (47) Vascular endothelial growth factor Rats
Ma et al. (2007) (48) Human transforming growth factor β1 Rats
Ma et al. (2008) (49) Human basic fibroblast growth factor Rats
Other Draghia et al. (1995) (50) Adenoviral vector AdRSV βgal Rats
Han et al. (2007) (51) pCMVβ and pN2/CMVβ Mice
Kim et al. (2009) (52) αβ-Crystallin siRNA Rats
Danielyan (2009) (53) Rat mesenchymal stem cells Mice
Specialized drug
delivery systems
N/A Harmon et al. (2014) (54) pGFP loaded nanoparticles Rats
Haque et al. (2014) (55) Venlafaxine loaded alginate nanoparticles Rats
Fazil et al. (2012) (56) Rivastigmine loaded chitosan nanoparticles Rats
Gao et al. (2007) (57) Ulex europeus agglutinin I modified nanoparticles Rats
This table summarizes a selection of animal studies which have evidence to confirm direct nose-to-brain transport of various drug categories
(i.e., small molecule drugs, biologics, and specialized drug delivery systems). For a comprehensive overview, see Kozlovskaya et al. (2014) (10)
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(MW=18.5 kDa), ovalbumin (45 kDa), leptin (16 kDa),
human nerve growth factor (MW=26.5 kDa), vascular
endothelial growth factor (MW=38.2 kDa), human
transforming growth factor β1 (MW=25 kDa), and human
basic fibroblast growth factor (MW=17.2 kDa) (41–49). All
these studies have evidence that initial transport into the
brain occurs by direct nose-to-brain transport via the
olfactory and trigeminal route.
In addition, few studies have focused on direct nose-to-
brain delivery of gene vectors and stem cells. The ability to
modify gene expression in CNS cells could be a promising
technique to treat chronic CNS diseases. For instance, a study
performed by Draghia et al. (1995) showed rats expressed β-
galactosidase in the brain after IN administration of
replication-defective adenoviral vector AdRSV β gal (50).
The affected structures in the brain were the olfactory bulb,
olfactory nucleus, locus coeruleus, and area postrema.
Furthermore, direct nose-to-brain transport has also been
observed in mice which were IN administered with pCMVβ
and pN2/CMVβ (51). Also, small interfering RNA (siRNA)
to αβ-crystallin was successfully delivered into the CNS of
rats after IN administration which resulted in a gene
knockdown in the olfactory bulb, amygdala, and hypothala-
mus (52). Lastly, fluorescently labeled rat mesenchymal stem
cells (MSC) have been observed in the olfactory bulb,
hippocampus, thalamus, cortex, and subarachnoid space of
mice 1 hour after direct nose-to-brain transport (53). IN
administration of stem cells might be an interesting technique
to treat neurodegenerative diseases.
Specialized Drug Delivery Systems
Over the past few years, specialized drug delivery
systems have been more extensively studied. For example,
Harmon et al. (2014) observed successful transfection of rat
brain cells adjacent to capillary endothelial cells located in the
rostral-caudal axis of the brain. This effect was produced by
giving rats an IN administration of unimolecularly compacted
nanoparticles which contained plasmid DNA encoding green
fluorescent protein (54). Although exact transport mecha-
nisms were not studied, green fluorescent protein expression
was shown to be significantly higher after using encapsulated
plasmid DNA than after using naked plasmid DNA.
Furthermore, direct nose-to-brain transport of
venlafaxine loaded alginate nanoparticles has been shown in
rats (55). Venlafaxine transport was significantly higher upon
encapsulation into alginate nanoparticles and subsequent IN
administration. Moreover, confocal laser scanning microscopy
results show rhodamin loaded alginate nanoparticles enter
the brain intact. Lastly, IN administration of rivastigmine
loaded chitosan nanoparticles in rats resulted in higher
rivastigmine brain concentrations than IV administration, as
determined by the brain homogenate method (56). Fazil et al.
(2012) used confocal laser scanning microscopy to qualita-
tively assess the biodistribution of rhodamin loaded chitosan
nanoparticles in the brain, which indicated chitosan nanopar-
ticles were intact upon entering the brain.
Aside from nanoparticles, many other techniques are
being developed which could enhance direct nose-to-brain
drug transport. For instance, using chitosan (coated) nano-
particles or cyclodextrin inclusion complexes provides a way
to improve the solubility of poorly soluble drugs (13,59).
Transport of poorly soluble drugs can also be enhanced by
using bio-adhesive emulsions, which have been demonstrated
to increase the brain uptake of small molecule drugs (13). An
interesting approach to reduce clearance and to achieve
targeted delivery involves the surface modification of nano-
particles to contain ligands which bind to specific cell types.
For example, nanoparticles covered with ulex europeus
agglutinin I, a ligand which binds to receptors present in the
olfactory region, have been shown to result in a higher drug
transport than unmodified nanoparticles when administered
IN in rats (57).
EVIDENCE FOR NOSE-TO-BRAIN DRUG TRAN
SPORT IN HUMANS
Although direct nose-to-brain drug transport has obtain-
ed increased attention, only one study so far has collected
quantitative PK data which confirmed this type of transport in
humans (60). Born et al. (2002) obtained PK evidence of
direct nose-to-brain transport in humans after IN administra-
tion of the peptides melanocortin (4–10), vasopressin, and
insulin (60). Peptide concentrations were measured in CSF
and systemic blood. CSF samples were taken from the
interspace between the fourth and fifth lumbar vertebrae.
After IN administration, melanocortin (4–10) and insulin
concentrations in the CSF increased while plasma levels
remained stable in comparison to baseline levels. However,
IN administered vasopressin was also present in systemic
blood, suggesting that either transport across the BBB and/or
direct uptake in the systemic circulation has been involved. In
contrast, Merkus et al. (2003) was unable to confirm direct
nose-to-brain transport of melatonin and hydroxocobalamin,
on the basis of plasma and CSF concentrations obtained in
humans, when comparing the extent of drug transport
enhancement after IN and IV administration (61). This might
be caused by preferential absorption of melatonin and
hydroxocobalamin into the systemic circulation (61). In
conclusion, direct nose-to-brain drug transport in humans
remains an unsolved issue.
Direct nose-to-brain drug transport in humans can also
be assessed indirectly, via a non-quantitative approach by
measuring drug-specific PD. In many studies, IN administra-
tion of the peptide oxytocin has been investigated (62). As
summarized by Chapman et al. (2013), IN administration of
oxytocin has been shown to increase trust in humans. These
results indicate transport through direct nose-to-brain trans-
port mechanisms as research performed by McGonigle (2012)
has demonstrated that oxytocin is unable to cross the BBB in
significant quantities (63). Thus, effects are likely to be caused
by oxytocin which entered the brain through direct nose-to-
brain mechanisms. However, no information was obtained
about the PK such as extent of drug transport into the brain.
Collecting quantitative PK evidence for direct nose-to-
brain transport in humans is difficult for several reasons. First
of all, many ethical issues arise when performing studies in
humans. Also, researchers have to perform human studies
according to laws and regulations developed to protect
human subjects from potential misconduct, which causes such
studies in humans to require more time and money than
studies in animals. Also, there are practical considerations.
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Ideally, researchers need to monitor unbound drug concen-
trations at the CNS target site in humans (3). However, due to
the ethical inaccessibility of the human brain for sampling,
this is not possible in humans. Therefore, CSF is usually
chosen as a surrogate for brain ECF concentrations due to its
accessibility via the spinal cord. However, drug concentra-
tions in CSF might not fully reflect drug concentrations found
in brain ECF (64–66). Furthermore, the collection of CSF
samples in humans requires highly specialized medical
personnel. In conclusion, performing quantitative nose-to-
brain studies in humans is complex and expensive but in
selected cases validations are essential to obtain an improved
understanding of human nose-to-brain drug delivery.
TRANSLATIONAL PK-PD OF NOSE-TO-BRAIN
REMOXIPRIDE TRANSPORT IN RATS
Translational investigations of direct nose-to-brain trans-
port from rats to humans could be of great significance for the
development of IN delivered CNS-active drugs. However, an
improved understanding of the predictive value of rats as a
preclinical animal model requires a mechanistic and struc-
tured approach. First we should learn from preclinical
translation between different conditions, especially PK-PD
following IV and IN drug administration. This is exemplified
by the following, so far unique, example. The PK model
developed by Stevens et al. (2011) shows the added value of
separation and quantitation of systemic and direct nose-to-
brain transport after IN administered remoxipride in freely
moving rats, in terms of extent and rates (34). As anesthesia
and stress significantly influence nose physiology, an ad-
vanced rat model for IN administration in freely moving
animals under minimum stress conditions was earlier devel-
oped and used accordingly (35). Remoxipride was adminis-
tered at different dosages, in freely moving rats, by the IN and
IV route. The plasma and brain ECF data were simultaneously
analyzed using non-linear mixed effects modeling to identify the
existence of direct nose-to-brain transport in a quantitative
manner. This PK model was then linked to a PD model that
could successfully predict PD also after IN administration,
indicating the validity of the structural PK-PD model.
PK Modeling of IV and IN Administered Remoxipride
in Rats
In Fig. 2, a novel PK model of remoxipride in rats after
IN administration is shown (34). This multi-compartment PK
model was developed by concurrent modeling of unbound
remoxipride concentrations in plasma and brain ECF, which
were collected following IV as well as IN administration (see
Table III for parameter description and values). Two
absorption compartments were identified in this model to
describe (1) the absorption rate constant of remoxipride from
the nasal cavity into the central compartment (ka13) and (2)
the absorption rate constant via direct nose-to-brain transport
(ka24). Remoxipride concentrations in plasma were repre-
sented by the central compartment and the elimination rate
constant of remoxipride from plasma was included (k30).
Furthermore, a peripheral compartment was incorporated to
account for remoxipride distribution rate constants from
plasma into peripheral tissues and organs (k35 and k53).
Concentrations of remoxipride in brain ECF were described
by the brain compartment, with brain elimination, and
transport rate constants of remoxipride across the BBB (k34
and k43 for inward and outward transport, respectively). This
model was subsequently evaluated by performing a visual
predictive check (VPC), showing that the simulated data by
the model were comparable to actual data obtained in the rat
studies, both following IV and IN remoxipride administration
indicating the validity of the structural PK model.
For absorption, in terms of extent, the total (absolute)
bioavailability of remoxipride following IN administration
was 89%. This was the sum of nose-to-systemic absorption
(F1, 22%) and direct nose-to-brain absorption (F2, 67%). This
indicates that direct nose-to-brain transport of remoxipride
was more extensive than nose-to-systemic absorption. In
terms of rates, remoxipride absorption from nose-to-
systemic compartment (ka13) was faster than absorption from
nose-to-brain (ka14). Interestingly, remoxipride elimination
from brain ECF (ka40) was shown to be significantly smaller
after IN drug administration than after IV drug administra-
tion. This suggests the existence of flip-flop kinetics (absorp-
tion-rate limited elimination of remoxipride from brain ECF).
Brain distribution, in terms of extent, was restricted as
indicated by the 0–4 h AUC (brain ECF)/AUC (plasma,
unbound) ratios (Kpuu) values of 0.3 and 0.2 after IN and IV
administration, respectively (which is an underestimation for
the IN administration, as unanticipated, the elimination half-
life was absorption-rate limited such that AUC 0–∞ values
could not be adequately determined). Then, in terms of rates,
transport across the BBB (k34 for the rate constant into and
k43 for the rate constant out of the brain) was determined to
be linear, indicating remoxipride transport mainly relied on
passive diffusion. Nonetheless, linearity in transport across
the BBB should never be automatically assumed. For
instance, influx and efflux transporters might both influence
the distribution of drugs between the central compartment
and the brain compartment and lead to a net impression of
linear transport in a certain concentration range.
In conclusion, this study demonstrated successful sepa-
ration and quantitation of systemic and direct nose-to-brain
transport in rats after IN administration of remoxipride, in
terms of extent as well as rate. The information on absorption
rates is important for the resulting PK profiles in the brain
that drive CNS drug effects, which is ultimately what we are
interested in.
PK-PD Modeling of IV and Translation to IN Administered
Remoxipride in Rats
The translational PK model as described above was
further developed into a translational PK-PD model using
pituitary hormone prolactin plasma levels as PD readout
(67,68) (Fig. 3). Prolactin is synthesized in the lactotrophs
of the pituitary gland and its release into plasma will
occur upon dopaminergic inhibition. Remoxipride, a
dopaminergic D2 receptor antagonist, is known to elevate
plasma prolactin levels following release from the
lactotrophs in the pituitary gland. After assessment of
baseline variation in prolactin plasma concentrations, the
prolactin plasma concentrations were measured upon
single IV doses of remoxipride, as well as following
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double low IV dosing of remoxipride with different time
intervals to get information on the rate of synthesis of
prolactin in the lactotrophs of the pituitary gland (67).
The final PK-PD model comprised the PK model for
remoxipride concentrations in plasma and brain ECF; a
dopamine antagonism component for the effect of
remoxipride brain ECF concentrations on stimulation of
prolactin release; a pool model incorporating prolactin
synthesis and storage in lactotrophs, as well as release
into and elimination from plasma; and a homeostatic
feedback component being the positive feedback for
prolactin plasma concentrations on prolactin synthesis in
the lactotrophs (34).
Subsequently, the translational value of this PK-PD
relationship developed for IN administration was evaluat-
ed on its translational value with regard to IN adminis-
tration. Thus, the dataset obtained in rats following IN
administration of the different doses of remoxipride was
used. The PK-PD relationship of remoxipride following IN
administration could be adequately predicted by
simulations of the PK-PD model, demonstrating successful
translation of remoxipride PK in rats between the two
distinct routes of drug administration.
TRANSLATIONAL PK AND PK-PD OF IV
REMOXIPRIDE FROM RATS TO HUMANS
Successful mathematical modeling of unbound
remoxipride PK in plasma and brain ECF in rats after IV
and IN drug administration, as shown in the previous study
example (34), provided the basis for the Bhumanized^ PK and
finally the PK-PD model (68). For translation of the
preclinical PK model to humans, allometric scaling was
applied and the Bhumanized^ PK model successfully predict-
ed existing plasma PK of remoxipride as measured in humans
(67). As no information on human brain ECF concentrations
were available, BBB transport scaling from rat to human was
made under the assumption of being linear as was the case in
rats. Thus, brain ECF PK in humans was predicted, without
the possibility of validation on existing human data.
Fig. 2. PK model of remoxipride delivered through IN administration. Compartment numbers are shown between brackets. Two absorption
compartments exist, which describe absorption of drug into the central compartment (systemic circulation) and another one which describes
direct drug absorption into the brain (direct nose-to-brain transport). The central compartment represents the remoxipride concentrations in
plasma. Distribution of drug into other tissues and organs is described by the peripheral compartment. Lastly, the brain compartment
represents drug concentrations in the ECF (34). Parameter values are provided in Table III
Table III. Parameter Estimates of Remoxipride PK in Rats Following IN Administration
Estimated
parameters Parameter description Value CV%
ka13 (/h) Absorption rate constant into the central compartment (systemic circulation) 1.54 11.8
ka24 (/h) Absorption rate constant of direct nose-to-brain transport 0.033 43.8
k30 (/h) Elimination rate constant from the central compartment 1.12 10.1
Fk40 (/h) Elimination rate constant from the brain compartment as fraction of k30 0.302 17.5
V3 (l/kg) Volume of distribution (central compartment) 0.088 13.6
V4 (l/kg) Volume of distribution (brain compartment) 0.873 24.1
V5 (l/kg) Volume of distribution (peripheral compartment) 0.417 8.60
Q4 (l/h/kg) Intercompartmental clearance between the central compartment and the brain compartment 0.70 19.9
Q5 (l/h/kg) Intercompartmental clearance between the central compartment and the peripheral compartment 1.20 10.2
FTOT Total bioavailability 0.89 4.60
F1 Bioavailability attributable to transport via initial absorption into the central compartment and subsequent
transport across the BBB
0.22 20.1
F2 Bioavailability attributable to transport directly from the nose into the brain 0.67 N/A
RV plasma Residual value of plasma 0.098 N/A
Estimated parameters are shown for the compartments presented in Fig. 2
CV coefficient of variation, F bioavailability, k elimination rate constant, ka absorption rate constant, Q inter-compartmental clearance, V
volume of distribution, RV residual variability (34)
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However, in rats, the brain ECF PK was found to be
indistinguishable from target site concentrations (i.e., showing a
direct and reversible effect on prolactine release from the pituitary
gland). Also, in the study by Movin-Osswald and Hammarlund-
Udenaes et al. (1995)\Phuman plasma prolactin concentrations
were assessed. Therefore, this PD information could be used to see
if the PD obtained in humans would be adequately predicted by
the Bhumanized^ PK-PD model for which drug-specific and
biological-system-specific parameters were obtained from the
literature. Indeed, it was demonstrated that the humanized PK-
PD model could satisfactorily predict PK-PD relationship of
remoxipride in humans. This indicates that the addition of PD
measurements can be of added value in the development of
preclinically derived PK-PD models for CNS active drugs.
TOWARDS PREDICTION OF NOSE-TO-BRAIN TRAN
SPORT IN HUMANS
Translational PK and PK-PD models developed on the
basis of preclinical data on CNS active drugs is a promising
approach to improve prediction of CNS target site concen-
trations in human and associated effects. For drugs that have
difficulties in distribution to the brain, the IN route of drug
administration may be a good alternative as a direct
absorption from the nose to the brain has been proven to
exist. The question is now how we can progress in predicting
nose-to-brain transport in humans. Here, we provide consid-
erations for translational preclinical studies, first those
following IV administration as a basis, then extended with
special considerations following IN administration (see Fig. 4
for the flow in model development).
For the translation of animal to human PK and PK-PD
following IVadministered drugs on the basis of preclinical data,
preclinical experiments will substantially improve if we include:
& unbound drug concentrations, as it is the unbound
drug concentration that drives transport processes
(BBB transport, intra-brain distribution, unbound
brain concentrations) and target interactions that
lead to drug effects (69,70). Brain ECF data are
often highly appropriate as many targets are facing
the ECF. However, also intracellular unbound con-
centrations may be needed (69–71). If CSF concen-
trations are used, then the relationship between brain
ECF and CSF should be considered (64–66,72).
& longitudinal measurements (PK, PD, disease stage), as
hereby information on rate and extent of mechanisms
can be unraveled (73).
& combined measurements on different levels of bio-
markers (plasma PK, brain PK, target interaction,
brain PD, signal transduction, disease (74)), in single
subjects, as data are connected (inter-dependency of
processes) and context (site of administration, spe-
cies, etc.) dependent, as knowledge on only one
individual processes is worthless and its role should
be investigated in multiple contexts. Also, to have
information on what concentrations can actually
represent target site concentrations, measurement of
concomitant effects of the drug is needed.
& influence of drug properties, as the combination of
drug properties and biological system characteristics
will determine the PK, and PK-PD
& advanced mathematical modeling to integrate all data
for the development of preclinical and Bhumanized^
mathematical models, including statistical approaches
to obtain insight into sources of variability. Advanced
mathematical modeling techniques are needed to
reveal complex relationships of body processes and
interactions of the body and the drug to be ultimately
integrated into mathematical models.
& human data to test validity of predictions of the
Bhumanized^ models.
The translation of drug PK and PK-PD from animals to
humans following IN administration will obviously be more
complicated than the examples presented above. This could
Fig. 3. Mechanism-based PK-PD model of remoxipride delivered in rats via IN drug administration. The PK part was based on the
compartment model of Stevens et al. (2011) (34) and the PD part on a pool model developed by Movin-Osswald et al. (1995) (67)
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make translational investigations of IN administered drugsmore
difficult but not impossible. To further work on the prediction of
human PK and PK-PD following IN administration, in addition
to the aforementioned points, we need to consider the:
& explicit distinction between the different absorption/
transport routes (i.e., absorption directly from nose to
the brain, absorption from the nose into the systemic
circulation, and distribution between the systemic
circulation and the brain), as the rate and extent of
each absorption/transport pathway may independent-
ly differ between rats and humans.
& inclusion of nose characteristics that differ between
preclinical species and humans.
& nasal metabolism and active transport as this may
implicate correct measurements due to the influence
of other processes.
& influence of formulations as absorption may be
influenced by formulation.
CONCLUSIONS
Over the past few decades, numerous IN adminis-
tered substances, such as small molecules, biologics, and
specialized drug delivery systems, have been shown to
enter the CNS of animals via direct nose-to-brain trans-
port while bypassing the BBB. Circumvention of the BBB
is facilitated by extracellular and intracellular transport
processes of drugs along the olfactory nerve and the
trigeminal nerve which provide direct entry points to the
CNS. However, direct nose-to-brain transport is mostly
dependent on transport along the olfactory nerve.
IN drug administration is non-invasive which means it
could be a promising drug delivery method for patients who
suffer from (chronic) CNS diseases. Preclinical animal studies
show encouraging results, confirming direct nose-to-brain
transport. However, multiple anatomical, physiological, and
histological differences exist between animals and humans.
Fig. 4. Global overview of steps in development of translational PK-PD models, as exemplified for remoxipride (34,67). First, a rat PK model is
developed on data following IVadministration only, followed by inclusion of also PD data, and simulated data by the model are validated on observed
data (a). Then, these models are further developed to include IN administration in the rat, and simulated data are validated on their prediction of
obtainedPKandPK-PDdata following IN administration (b). Subsequently, the rat IVPKandPK-PDmodels are Bhumanized^ by appropriated scaling
and simulated data by the humanizedmodel is validated on obtained human PK and PK-PD data (c). Finally, it would be possible to further develop the
humanized PK and PK-PD model as developed for IVadministration, by further scaling of nose characteristics from rat to human
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Therefore, it is of great importance to investigate the predictive
value of preclinical animal models within the context of direct
nose-to-brain transport. This can be investigated by using an
integrated approach which is based on the collection of
quantitative PK and PK-PD data over time.
Quantitative PK and PK-PD data on unbound drug
concentrations after IN versus IV administration obtained
from animals provides the opportunity to create advanced
mathematical PK and PK-PD models that can be scaled to
humans. Using such an integrated approach would provide
insight into the predictive value of preclinical animal models.
This would benefit the development of intranasally adminis-
tered CNS-active drugs.
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